Home > Insider Trading > Filing (0001415889-24-020047)

Filing Details

Accession Number:: 0001415889-24-020047
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-07-24 16:27:11
Reporting Period:: 2024-07-22

Accepted Time:: 2024-07-24 16:27:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817241	Artiva Biotherapeutics Inc.	ARTV	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1346824	Ra Capital Management, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	No	No
1384859	Peter Kolchinsky	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1619841	M. Rajeev Shah	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1780117	Ra Capital Nexus Fund, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No
1883840	Ra Capital Nexus Fund Iii, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-07-22	725,391	$0.00	725,391	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-07-22	264,571	$0.00	264,571	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-07-22	68,320	$0.00	68,320	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-07-22	323,181	$10.20	1,048,572	No	4	J	Indirect	See footnotes
Common Stock	Acquisiton	2024-07-22	138,506	$10.20	138,506	No	4	J	Indirect	See footnotes
Common Stock	Acquisiton	2024-07-22	7,645,007	$12.00	8,693,579	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2024-07-22	688,326	$12.00	826,832	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	J	Indirect	See footnotes
No	4	J	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2024-07-22	564,372	$0.00	564,372	$0.00
Common Stock	Series A Preferred Stock	Disposition	2024-07-22	210,898	$0.00	210,898	$0.00
Common Stock	Series A Preferred Stock	Disposition	2024-07-22	68,320	$0.00	68,320	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-07-22	161,019	$0.00	161,019	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-07-22	53,673	$0.00	53,673	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock wasconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Held directly by the Fund.
Held directly by the Nexus Fund.
Held directly by the Account.
Represents the conversion of outstanding simple agreement for future equity in the amount of $3,296,448.20 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
Represents the conversion of outstanding simple agreement for future equity in the amount of $1,412,763.51 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
Held directly by Nexus Fund III.